Emisphere Technologies, Inc. is a biopharmaceutical company specializing in oral drug delivery solutions for macromolecules that traditionally require injection. Established in 1994 and headquartered in Woodcliff Lake, New Jersey, the company develops proprietary Eligen® carrier technology designed to improve the absorption of peptides, proteins and other large molecules across the gastrointestinal tract. Emisphere’s platform aims to transform how chronic diseases are treated by enabling oral dosing of therapies that have historically faced bioavailability challenges.
At the core of Emisphere’s business is the Eligen® carrier system, a small-molecule absorption enhancer that can be co-formulated with a wide range of therapeutic agents. This technology has been studied in multiple clinical trials, demonstrating its potential to enhance the oral uptake of insulin, calcitonin, heparin and other biotherapeutics. Emisphere offers formulation development services and licensing partnerships to pharmaceutical companies seeking to expand their product portfolios with orally administered treatments for diabetes, osteoporosis, cardiovascular conditions and other indications.
Over the years, Emisphere has collaborated with leading global pharmaceutical firms to advance its technology. Strategic alliances have included research and licensing agreements with prominent industry players in North America, Europe and Asia. These partnerships underscore the broad applicability of Emisphere’s Eligen® platform and its relevance to both small-molecule drugs and large biologics.
Emisphere’s leadership team brings extensive experience in drug development, regulatory affairs and commercial strategy. The company is led by CEO David J. Johnston, who has over two decades of experience in biotechnology innovation and business development. Supported by a seasoned board of directors and a scientific advisory panel, Emisphere continues to pursue new licensing opportunities and research collaborations aimed at delivering oral versions of life-changing therapies to patients worldwide.
AI Generated. May Contain Errors.
